Fungal Resistance in Dermatophyte Infection
May 10, 2025 updated by: Hagar El Sayed, Cairo University
Species Identification and Antifungal Susceptibility Testing of Dermatophytes Isolated From Patients Attending Dermatology Outpatient Clinic at Kasr Alainy Hospitals
The aim of the study is to compare the efficiency of broth microdilution versus disk diffusion method for antifungal drug susceptibility testing of the most used drugs in dermatophytosis treatment.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Estimated)
42
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
N/A
Sampling Method
Probability Sample
Study Population
Patients with dermatophytic skin infection
Description
Inclusion Criteria:
- Patients diagnosed clinically with dermatophytosis, any age group and any sex
Exclusion Criteria:
- Patients under either Local or systemic antifungal treatment
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Antifungal susceptibility testing (AFST)
|
testing the fungal susceptibility to different drugs
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Precent susceptibility to each drug
Time Frame: 3 months
|
Measure the area of inhibition zone of the drugs to the fungus on the culture
|
3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
June 1, 2025
Primary Completion (Estimated)
July 1, 2025
Study Completion (Estimated)
August 1, 2025
Study Registration Dates
First Submitted
December 8, 2024
First Submitted That Met QC Criteria
December 8, 2024
First Posted (Actual)
December 11, 2024
Study Record Updates
Last Update Posted (Actual)
May 14, 2025
Last Update Submitted That Met QC Criteria
May 10, 2025
Last Verified
May 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Bacterial Infections and Mycoses
- Skin Diseases, Infectious
- Mycoses
- Infections
- Dermatomycoses
- Anti-Infective Agents
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Enzyme Inhibitors
- Steroid Synthesis Inhibitors
- Hormone Antagonists
- Cytochrome P-450 Enzyme Inhibitors
- Anti-Infective Agents, Local
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 CYP2C9 Inhibitors
- 14-alpha Demethylase Inhibitors
- Antifungal Agents
- Clotrimazole
- Miconazole
Other Study ID Numbers
- Cutaneous Fungal resistance
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.